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predicting mortality in a prospective cohort of
patients with sepsis requiring ICU management
Yok-Ai Que1, Frederik Delodder1, Idris Guessous2,3, Rolf Graf4, Martha Bain4, Thierry Calandra5, Lucas Liaudet1 and
Philippe Eggimann1*
Abstract
Introduction: Biomarkers, such as C-reactive protein [CRP] and procalcitonin [PCT], are insufficiently sensitive or
specific to stratify patients with sepsis. We investigate the prognostic value of pancreatic stone protein/
regenerating protein (PSP/reg) concentration in patients with severe infections.
Methods: PSP/reg, CRP, PCT, tumor necrosis factor-alpha (TNF-a), interleukin 1 beta (IL1-b), IL-6 and IL-8 were
prospectively measured in cohort of patients ≥ 18 years of age with severe sepsis or septic shock within 24 hours
of admission in a medico-surgical intensive care unit (ICU) of a community and referral university hospital, and the
ability to predict in-hospital mortality was determined.
Results: We evaluated 107 patients, 33 with severe sepsis and 74 with septic shock, with in-hospital mortality rates
of 6% (2/33) and 25% (17/74), respectively. Plasma concentrations of PSP/reg (343.5 vs. 73.5 ng/ml, P < 0.001), PCT
(39.3 vs. 12.0 ng/ml, P < 0.001), IL-8 (682 vs. 184 ng/ml, P < 0.001) and IL-6 (1955 vs. 544 pg/ml, P < 0.01) were
significantly higher in patients with septic shock than with severe sepsis. Of note, median PSP/reg was 13.0 ng/ml
(IQR: 4.8) in 20 severely burned patients without infection. The area under the ROC curve for PSP/reg (0.65 [95% CI:
0.51 to 0.80]) was higher than for CRP (0.44 [0.29 to 0.60]), PCT 0.46 [0.29 to 0.61]), IL-8 (0.61 [0.43 to 0.77]) or IL-6
(0.59 [0.44 to 0.75]) in predicting in-hospital mortality. In patients with septic shock, PSP/reg was the only biomarker
associated with in-hospital mortality (P = 0.049). Risk of mortality increased continuously for each ascending
quartile of PSP/reg.
Conclusions: Measurement of PSP/reg concentration within 24 hours of ICU admission may predict in-hospital
mortality in patients with septic shock, identifying patients who may benefit most from tailored ICU management.
Introduction
Despite significant improvements in clinical manage-
ment, including systematic multimodal approaches [1],
severe forms of infections, such as severe sepsis and sep-
tic shock, are the leading causes of mortality in patients
admitted to the intensive care unit (ICU) [2-4]. Over the
last two decades, several promising therapeutic strategies
designed to specifically target pathogen or host-related
mediators involved in the septic process have failed to
reduce mortality [5-7], and this failure is due, in part, to
the heterogeneity of both microbial agents and host
inflammatory responses [8]. Since therapeutic strategies
should be adapted to each individual patient, the identifi-
cation of patients who are at high risk of death and who
might benefit most from early and aggressive treatment
would represent a critical step toward such tailored man-
agement [9]. Serum biomarkers may assist clinicians in
risk stratification and decision-making processes [10]. An
ideal biomarker in patients with sepsis should improve
early diagnosis and predict early deterioration toward
organ failure and eventually death, thereby identifying
patients requiring additional aggressive treatments [11].
Owing to a lack of specificity or sensitivity or both (for
example, C-reactive protein (CRP) and procalcitonin
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(PCT) [10,12]) or to a narrow time window of expression
(for example, interleukin-6 (IL-6) and IL-8 [8]), currently
used biomarkers do not fulfill such requirements. There-
fore, further efforts are needed to identify novel sepsis
biomarkers.
Pancreatic stone protein/regenerating protein (PSP/reg)
is constitutively secreted by pancreatic acinar cells into
pancreatic juice along with zymogens and is also secreted
by subsets of intestinal and gastric cells [13]. Although its
precise physiological roles remain only partly defined, it
appears to have protective functions by promoting cellular
proliferative responses during beta-cell regenerative pro-
cesses and epithelial repair [13]. PSP/reg is upregulated
during acute and chronic pancreatitis; in animals, its
expression may be induced by stress conditions in the
absence of any pancreatic inflammation. In a recent clini-
cal study, serum concentrations of PSP/reg were found to
be markedly elevated after trauma, and PSP/reg concentra-
tions showed a close correlation with the severity of post-
trauma infection [14]. Furthermore, PSP/reg was found to
bind to polymorphonuclear cells and seemed to induce or
maintain their activation or both; thus, PSP/reg might
serve as an acute-phase protein [14].
We therefore hypothesized that PSP/reg concentration
may represent a potential biomarker of sepsis-related
inflammation. To address this hypothesis, we prospectively
measured plasma concentrations of PSP/reg within 24
hours of ICU admission in 107 patients with clinically
diagnosed forms of severe infections. (Some of the results
of these studies have been reported in the form of an
abstract [15].)
Materials and methods
Patient population
This study was performed between February 2008 and
June 2010 in a 32-bed adult medico-surgical ICU of a
community and referral university hospital. Patients who
were at least 18 years old were evaluated within 24 hours
of ICU admission for severe sepsis or septic shock. Owing
to organizational constraints, inclusion was prospective
but could not be strictly consecutive. The study was
approved by the Institutional Review Board (Commission
cantonale [VD] d’éthique de la recherche sur l’être
humain, Lausanne, Switzerland). Written informed con-
sent was obtained from patients or relatives. Infections,
sepsis, severe sepsis, and septic shock were defined accord-
ing to commonly used criteria [16] (Additional file 1).
Patients were followed until death or discharge from the
hospital. In-hospital mortality was the primary endpoint.
Data collection
In addition to recording clinical variables collected from
the computerized information system (Metavision;
IMDsoft, Tel Aviv, Israel), we recorded the age, sex,
admission category, origin (home, emergency room, or
ward), and McCabe score of each patient [17]. Severity
of illness was evaluated on the first day in the ICU by
using the Simplified Acute Physiology Score (SAPS) II
[18] and III [19] and the Acute Physiology and Chronic
Health Evaluation II (APACHE II) score [20]. Organ
dysfunction was evaluated by the Sequential Organ Fail-
ure Assessment (SOFA) score [21]. Severe comorbidities
were described by using definitions of the APACHE II
score and SAPS II and III.
Measurement of plasma biomarker concentrations
At the time of enrollment, heparinized plasma was
obtained from each patient for measurements of biomar-
kers. (Detailed measurement protocols are presented in
Additional file 1.) PSP/reg was quantified by using an iso-
form-specific enzyme-linked immunosorbent assay as
described previously [14]. Briefly, plasma samples were
incubated with plates precoated with guinea pig anti-PSP/
reg antibody. Rabbit anti-PSP/reg was added and subse-
quently detected by phosphatase-conjugated anti-rabbit
immunglobulin G. This assay had a detection limit of less
than 0.1 ng/mL and an inter-plate variance of less than
10% [14].
Statistical analysis
Continuous variables are reported as mean and standard
deviation (SD) or medians and interquartile ranges
(IQRs) as indicated. Categorical variables are reported as
frequencies and percentages. Because the distributions of
the biomarkers were skewed, continuous variables
between severity of infection or between survivors and
non-survivors were compared by using non-parametric
two-sided Wilcoxon-Mann-Whitney rank sum tests.
APACHE II, SAPS II and III, and SOFA scores are
expressed as mean and SD.
Receiver operating characteristic (ROC) curves using
concentrations of acute-phase proteins (CRP, PCT, and
PSP/reg), pro-inflammatory cytokines (IL-6, IL-8, and IL-
10), and acute severity scores (APACHE II and SAPS II
and III) as independent variables and mortality as a depen-
dent variable were computed first for the entire population
and then specifically for patients with septic shock only.
From these curves, we computed areas under the curve
(AUCs) and 95% confidence intervals (CIs) to assess the
discrimination ability of each marker for predictive
purposes. Multiple logistic regression analysis and
age-adjusted predicted hospital mortality (expressed as
age-adjusted beta regression coefficients) were used to
assess the relationship (for example, linearity and distribu-
tion) between biomarker concentrations and in-hospital
mortality. Finally, we estimated the odds ratios (ORs) for
mortality and trends across biomarker quartiles. All P
values were two-sided, and statistical significance was set
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at a P value of less than 0.05. We used Stata (version 11.2;
StataCorp LP, College Station, TX, USA) for data proces-
sing and analyses.
Results
Patient characteristics
From February 2008 to June 2010, 177 patients were
prospectively screened (Additional file 2, Figure S1); of
these, 25 (14%) declined consent and 18 (10%) died
before consent could be obtained. We included 107
patients: 33 (30%) with severe sepsis and 74 (70%) with
septic shock (Table 1). There were more males than
females in each subgroup. Sixty-one (57%) and 46 (43%)
patients presented with community-acquired and noso-
comial infections, respectively. Over 75% of patients had
pulmonary or abdominal infections, and high percen-
tages were infected with Streptococcus pneumoniae
(18.7%) or Escherichia coli (21.5%). The overall in-hospi-
tal mortality rates were 20.5%, 9% for patients with
severe sepsis, and 25.7% for patients with septic shock.
Most patients had at least one comorbid condition, but
fewer than 14% had McCabe scores predicting rapidly
fatal outcome.
Plasma levels of CRP, PCT, PSP/reg, and inflammatory
cytokines in patients with severe sepsis and septic shock
Plasma concentrations of the various biomarkers in rela-
tion to the severity of infection (severe sepsis or septic
shock) are presented in Table 2 and in Figure S2 of Addi-
tional file 3. In comparison with the concentrations of
CRP, those of the acute-phase proteins PCT and PSP/reg
and the pro-inflammatory cytokines IL-6 and IL-8 were
significantly higher in patients with septic shock than in
patients with severe sepsis, and the median PSP/reg con-
centration was about five times higher in patients with
septic shock (343.5 ng/L) than in patients with severe
sepsis (73.5 ng/L). As expected, the acute severity scores
(APACHE II and SAPS II and III) were significantly
higher in patients with septic shock than in those with
severe sepsis.
PSP/reg was further measured in the plasma of burned
patients who were previously admitted to our ICU and in
whom trace element supplementation resulted in
improved clinical outcome, including fewer pulmonary
infections and better wound healing [22]. In these 20
patients with severe non-infectious inflammation (mean
age of 43 ± 16 years, mean total surface body area burned
of 45% ± 22%, and median SAPS II of 32 and IQR of 14),
the median PSP/reg within the first 24 hours of admis-
sion was 13.0 ng/mL (IQR of 4.8). Figure S3 of Additional
file 4 displays the individual values of PSP/reg in these
patients compared with those with severe sepsis and sep-
tic shock.
Association between plasma levels of CRP, PCT, PSP/reg,
and inflammatory cytokines and in-hospital mortality
We assessed the relationship between the plasma concen-
trations of CRP, PCT, and PSP/reg; the concentrations of
inflammatory cytokines; the number of leukocytes; severity
scores (APACHE II, SAPS II and III, and SOFA); and in-
hospital mortality in patients with severe sepsis or septic
shock (Table 3 and Additional file 1, Table S1). Overall,
regardless of severity, PSP/reg concentrations and SAPS III
scores were the only variables that differed significantly
between survivors and non-survivors (Table 3). Despite
their association with severity, IL-6, IL-8, PCT, APACHE
II, and SAPS II were not associated with mortality. Among
patients with septic shock (Additional file 1, Table S1),
PSP/reg remained the only biomarker significantly asso-
ciated with mortality (P = 0.049).
Biomarkers and severity scores as predictors of in-
hospital mortality
We used AUC analysis to further explore the capacity of
each parameter to predict mortality at ICU admission
(Figure 1 and Additional file 1, Table S2) within our parti-
cular population of patients admitted with a diagnosis of
severe sepsis or septic shock. ROCs were computed for
the entire patient cohort (Figure 1a) and for patients with
septic shock (Figure 1b). When applied to the whole popu-
lation, PSP/reg, IL-8, and IL-6 yielded the highest discrimi-
native value with AUCs (95% CIs) of 0.65 (0.51 to 0.80),
0.61 (0.43 to 0.77), and 0.59 (0.44 to 0.75), respectively. In
contrast, the AUCs (95% CIs) of CRP and PCT were
0.44 (0.29 to 0.60) and 0.46 (0.29 to 0.61), respectively
(Figure 1a and Additional file 1, Table S2). Similar patterns
and AUC values were observed when the analysis was
restricted to patients with septic shock (Figure 1b and
Additional file 1, Table S2).
PSP/reg showed a more uniform and linear distribution
than other biomarkers throughout the range of probability
of in-hospital mortality (Figure 2a, b). Only seven patients
with septic shock (9.5%) presented with IL-6 concentra-
tions in the three highest quartiles in comparison with
20 (27%) for PSP/reg (Figure 2b).
The age-adjusted beta regression coefficients - that is,
the change in probability of in-hospital mortality per stan-
dard unit (one SD) change in biomarker concentration -
were 0.16 (SD of 0.07) per 100 ng/mL increase of PSP/reg
(P = 0.03), 0.17 (SD of 0.10) per 50 ng/mL increase of IL-6
(P = 0.08), and -0.00076 (SD of 0.0587) per 10 ng/mL
increase of PCT (P = 0.99). When restricted to patients
with septic shock, the age-adjusted beta regression coeffi-
cients were 0.16 (SD of 0.08) per 100 ng/mL increase of
PSP/reg (P = 0.048), 0.15 (SD of 0.10) per 50 ng/mL
increase of IL-6 (P = 0.15), and -0.0167 (SD of 0.062) per
10 ng/mL increase of PCT (P = 0.79).
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Table 1 Patient characteristics, by sepsis severity (n = 107)
Patient characteristic All Severe sepsis Septic shock
(n = 107) (n = 33) (n = 74)
Demographics
Age in years, mean ± SD 59 ± 17.5 55 ± 20 61 ± 16
Male/Female 62/45 20/13 42/32
Admission categories
Medical 72 (67%) 24 (73%) 48 (65%)
Scheduled surgery 4 (4%) 0 (0%) 4 (5%)
Unscheduled surgery 31 (29%) 9 (27%) 22 (30%)
Origin
Community (home/emergency room) 61 (57%) 18 (54.5%) 43 (58.1%)
Nosocomial (hospital transfer) 46 (43%) 15 (45.5%) 31 (41.9%)
Referral from other hospital 20 (18.7%) 5 (15.2%) 15 (20.3%)
Operating room 3 (2.8%) 1 (3%) 2 (2.7%)
Ward 14 (13.1%) 6 (18.2%) 8 (10.8%)
Intermediate care 9 (8.4%) 3 (9.1%) 6 (8.1%)
Severe comorbidities
Chronic obstructive pulmonary disease 17 (15.8%) 5 (15.1%) 12 (16.2%)
Cardiac insufficiency 16 (15%) 2 (6%) 14 (18.9%)
Cirrhosis 8 (7.5%) 1 (3%) 7 (9.5%)
End-stage renal disease 15 (14%) 3 (9%) 12 (16.2%)
Immunodeficiencya 13 (12.1%) 2 (6%) 11 (14.9%)
Insulin-dependent diabetes 6 (5.6%) 1 (3%) 5 (6.7%)
Score, mean ± SD
APACHE II 30 ± 8 27 ± 86 31 ± 8
SAPS II 71 ± 17 65 ± 16 74 ± 17
SAPS III 76 ± 18 67 ± 21 80 ± 15
SOFA (day 1) 11 ± 3 11 ± 3 11 ± 3
McCabe score
Non-fatal 63 (59%) 22 (66.6%) 41 (55%)
Ultimately fatal (< 5 years) 30 (28%) 7 (21.2%) 23 (31%)
Rapid fatal (< 6 months) 14 (13%) 4 (12.2%) 10 (14%)
Infection sites
Pulmonary 37 (34.5%) 14 (42.4%) 23 (31%)
Abdominal 38 (36%) 7 (21.2%) 31 (41.9%)
Bloodstream 7 (6.5%) 4 (12.1%) 3 (4.1%)
CNS and ENT 5 (4.6%) 2 (6.1%) 3 (4.1%)
Urinary tract 5 (4.6%) 2 (6.1%) 3 (4.1%)
Soft tissues 13 (12%) 4 (12.1%) 9 (12.1%)
Miscellaneous 2 (1.8%) 0 (0%) 2 (2.7%)
Microbiology
Gram-positive (number of positive blood cultures) 41 (38.3%) 17 (51.5%) 24 (32.4%)
Staphylococcus aureus (8) 8 (7.5%) 5 (15.1%) 3 (4.1%)
Streptococcus pyogenes (2) 10 (9.3%) 2 (6.1%) 8 (10.8%)
Streptococcus pneumoniae (8) 20 (18.7%) 8 (24.2%) 12 (16.1%)
Other (2) 3 (2.8%) 2 (6.1%) 1 (1.4%)
Gram-negative 45 (42%) 13 (39.4%) 32 (43.2%)
Escherichia coli (14) 23 (21.5%) 5 (15.2%) 18 (24.3%)
Other Enterobacteriacae (5) 7 (6.5%) 1 (3.05%) 6 (8.1%)
Pseudomonas aeruginosa (5) 6 (5.6%) 3 (9.05%) 3 (4.1%)
Other (5) 9 (8.4%) 4 (12.1%) 5 (6.7%)
Fungi 3 (2.8%) 0 (0%) 3 (4.1%)
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Moreover, in contrast to IL-6 and PCT, the age-
adjusted ORs (95% CIs) of mortality among patients
with septic shock increased continuously across PSP/reg
quartiles: PSP/reg OR 1.0 [reference group], 1.5 (0.19 to
10.0), 5.1 (0.8 to 32.0), and 6.4 (0.96 to 42.0), respec-
tively (test for trend P = 0.02). For IL-6 quartiles, the
age-adjusted ORs (95% CIs) for mortality among
patients with septic shock were 1.0 [reference group],
2.0 (0.36 to 10.0), 1.3 (0.23 to 7.5), and 2.4 (0.45 to
12.0), respectively (test for trend P = 0.41), whereas, for
PCT, the corresponding values were 1.0 [reference
group], 0.4 (0.7 to 2.0), 0.7 (0.16 to 3.1), and 0.4 (0.08 to
1.9), respectively (test for trend P = 0.35).
Discussion
Our results suggest that PSP/reg, a novel acute-phase
protein, measured within 24 hours of ICU admission,
may predict the risk of mortality in patients with severe
sepsis and septic shock. PSP/reg was identified in
patients with pancreatitis and further associated with
islet regeneration [13,23]. The findings that its expres-
sion was not restricted to the pancreas [24,25] and that
it can be induced by stress in animals [26] opened the
way to investigate its role as a potential acute-phase
protein. A recent study in 83 trauma patients reported
that PSP/reg concentrations were 15-fold higher from
baseline (5 to 15 ng/mL) in patients developing septic
complications [14].
Our results suggest that PSP/reg, measured within 24
hours of ICU admission, may be used as a biomarker to
identify septic patients at highest risk of death. PSP/reg
performed better than CRP and PCT, which are widely
used to diagnose infection but which, owing to their
poor accuracy in this indication, should not be used to
predict disease outcome [10,12,27,28]. A similar obser-
vation was recently reported in a cohort of 101 patients
with ventilator-associated pneumonia [29]. In this
cohort, PSP/reg measured after 7 days of mechanical
ventilation predicted subsequent organ failure develop-
ment and, eventually, outcome. A major advantage of
Table 1 Patient characteristics, by sepsis severity (n = 107) (Continued)
Candida albicans (1) 1 (1%) 0 (0%) 1 (1.4%)
Other (0) 2 (1.8%) 0 (0%) 2 (2.7%)
H1N1 1 (1%) 0 (0%) 1 (1.4%)
Undocumented 17 (15.9%) 3 (9.1%) 14 (18.9%)
Outcome
Hospital mortality 22 (20.6%) 3 (9%) 19 (25.7%)
Values are presented as numbers (percentages) of patients unless indicated otherwise. aHIV, solid organ transplant recipients, hematological malignancies,
chronic use of more than 30 mg per day prednisone equivalents. APACHE II, Acute Physiology and Chronic Health Evaluation II; CNS, central nervous system; ENT,
ear, nose, and throat; SAPS, Simplified Acute Physiology Score; SD, standard deviation; SOFA, Sequential Organ Failure Assessment.
Table 2 Plasma concentrations of biomarkers and severity scores, by sepsis severity
Biomarker or severity scoring system All (n = 107) Severe sepsis (n = 33) Septic shock (n = 74)
Median IQR Median IQR Median IQR Test
Acute-phase proteins
CRP, mg/L 253.5 155.5 218 152 266 158 0.35
PCT, ng/mL 25.12 48.98 11.96 20.94 39.25 49.99 < 0.0001
PSP/reg, ng/mL 241.25 399.00 73.5 180.25 343.5 369 < 0.0001
Cytokines
TNF-a, pg/ml 2.47 7.07 1.93 7.07 2.41 6.97 0.86
IL-1b, pg/mL 6.43 21.04 1.96 15.53 8.175 24.54 0.21
IL-6, pg/mL 1,173.28 6,749.6 544.07 1,237.48 1,755.34 14,514.13 0.004
IL-8, pg/mL 438.95 1,804.67 184.15 408.72 681.775 3,273.42 0.0001
IL-10, pg/mL 149.37 672.82 76.24 239.67 199.94 706.22 0.045
Other
Leukocytes, G/L 13.5 14.2 13.5 5.5 13.3 17.1 0.28
APACHE II 28 14 26 14 29 14 0.04
SAPS II 69 26 62 29 71 27 0.02
SAPS III 76 27 69 28 79.5 25 0.001
SOFA 11 4 10 5 11 5 0.35
APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; PCT, procalcitonin; PSP/reg,
pancreatic stone protein/regenerating protein; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TNF-a, tumor necrosis factor-
alpha.
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Table 3 Plasma concentrations of biomarkers and severity scores, by survival status
Biomarker or severity scoring system All (n = 107)
Death (n = 22) Survival (n = 85)
Median IQR Median IQR P value
Acute-phase proteins
CRP, mg/L 203 188 266 154 0.21
PCT, ng/mL 17.485 51.75 26.22 44.75 0.57
PSP/reg, ng/mL 397 435.9 216.1 379 0.02
Cytokines
TNF-a, pg/ml 2.655 10.36 2.35 6.73 0.46
IL-1b, pg/mL 0.795 34.02 7.6 20.41 0.46
IL-6, pg/mL 2,415.58 16,219.42 790.53 6,467.74 0.16
IL-8, pg/mL 757.775 10,597.73 414.88 1,597.6 0.11
IL-10, pg/mL 416.18 1393.6 136.76 494.89 0.17
Other
Leukocytes, G/L 13.85 14.45 13.4 14.2 0.27
APACHE II 32 12 27 13 0.4
SAPS II 71.5 26 68 27 0.52
SAPS III 87.5 27 74 25 0.01
SOFA 11 6 11 4 0.9
APACHE II, Acute Physiology and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; IQR, interquartile range; PCT, procalcitonin; PSP/reg,
pancreatic stone protein/regenerating protein; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment; TNF-a, tumor necrosis factor-
alpha.
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Figure 1 Receiver operating characteristic (ROC) curves for the entire patient cohort (a) and for patients with septic shock (b). Areas
under the curve (AUCs) were determined for acute-phase proteins, pro-inflammatory cytokines, and severity scores. APACHE II, Acute Physiology
and Chronic Health Evaluation II; CRP, C-reactive protein; IL, interleukin; PCT, procalcitonin; PSP, pancreatic stone protein; SAPS, Simplified Acute
Physiology Score; SOFA, Sequential Organ Failure Assessment.
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PSP/reg over the currently available predictors of disease
evolution, such as cytokines, may be its presence in the
plasma of all septic patients at the time of ICU admis-
sion. This sharply contrasts with the pro-inflammatory
cytokines tumor necrosis factor-alpha, IL-1, and IL-6,
which showed very good predictive values in dedicated
trials [30,31] but whose use in daily life was finally ham-
pered by their short window of expression in plasma,
making them difficult to interpret at the bedside in a
population of patients in whom the time between the
onset of sepsis and the blood test cannot be standar-
dized [32].
The strength of our study is that it is representative of
the usual population of patients admitted to a mixed ICU.
Inclusion criteria were simple, making the setting corre-
spond to what any clinician could encounter in his or her
daily practice, increasing the chances of PSP/reg measure-
ment implementation at the bedside to predict patient
outcome. The small number of patients may explain the
absence of a correlation of APACHE II or SAPS II with
mortality in a cohort of patients with severe infections
[33]. In this context, the strong association of PSP/reg with
mortality might be viewed as indirect evidence of its better
specificity for sepsis. The fact that stratification of patients
with sepsis could occur within 24 hours of admission
would eventually exclude from stratification most patients
without a clear diagnosis of sepsis (this strategy resulted in
a low number of non-documented infections in our study)
as well as those dying rapidly despite resuscitation and for
whom very early evaluation of prognosis (< 18 hours)
would probably not result in a different initial manage-
ment [1].
This single-center study also has several limitations.
First, since 18 (10%) patients died before consent could be
obtained, selection bias cannot be excluded. This may also
have contributed to the lower mortality rate of our
patients with septic shock compared with rates reported
earlier [2-4]. Second, owing to organizational constraints,
patient recruitment was restricted to periods when co-
investigators worked as attending physicians. Third, since
the purpose of the study was to explore the accuracy of
PSP/reg compared with that of other commonly used or
studied predictors (such as pro-inflammatory cytokines) in
a homogenous population of patients with a definite diag-
nosis of sepsis at the time of ICU admission and not
between populations of septic and non-septic patients,
patients without sepsis were not included. This may have
resulted in an apparently modest absolute predicting
power (ROC of 0.65). Finally, owing to the relatively small
number of patients, these results require further validation
in a larger and preferentially multicentric cohort of
patients with sepsis.
Though preliminary, our data still suggest that PSP/reg
determination could be useful in the stratification of
patients with septic shock. After initial resuscitation, PSP/
reg blood levels that are measured within 24 hours of ICU
admission may help to detect patients at high risk of death
and to reduce the number of those susceptible to receive
new and costly adjunctive treatments, such as specific
immunotherapy [34], anti-cytokines [35], or extra-corpor-
eal lipopolysaccharide removal [36].
Conclusions
We conclude that a single measurement of PSP/reg con-
centration within 24 hours of ICU admission stratifies
patients with sepsis according to severity of infection
and risk of death. If our findings are confirmed by
further studies, this promising biomarker may help phy-
sicians to tailor treatments to individual patients accord-
ing to risk of death.
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Figure 2 Probability of in-hospital mortality upon admission among the entire patient cohort (a) and patients with septic shock (b).
Probabilities are according to their concentrations of plasma pancreatic stone protein/regenerating protein (PSP/reg) (crosses), interleukin-6 (IL-6)
(open circles), and procalcitonin (PCT) (closed circles). Gradients of grey correspond to quartiles of biomarker concentrations.
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Key messages
• Commonly used biomarkers, such as C-reactive
protein and procalcitonin, are insufficiently sensitive
or specific to stratify patients with sepsis.
• Pancreatic stone protein/regenerating protein
(PSP/reg) is an accurate biomarker to stratify septic
patients admitted to intensive care units (ICUs).
• PSP/reg blood measurement within 24 hours of ICU
admission predicts risk of death more accurately than
procalcitonin and pro-inflammatory cytokines.
• PSP/reg may help to identify, among all patients
admitted for sepsis, those most susceptible to benefit
from aggressive management.
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